Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study

[1]  Ph.D. M. S. Mahaley Jr. M.D..  Neuro-oncology index and review (adult primary brain tumors) , 2006, Journal of Neuro-Oncology.

[2]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[3]  M. Prados,et al.  Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S B Green,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.

[6]  Y. Ayakawa,et al.  [Minimal effective dose of perfluorochemical emulsion as a radiosensitizer]. , 1989, Nihon Gan Chiryo Gakkai shi.

[7]  M. Prados,et al.  Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine. , 1989, Neurosurgery.

[8]  B. Teicher,et al.  Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. , 1987, Cancer research.

[9]  S. Phuphanich,et al.  Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. , 1986, Cancer treatment reports.

[10]  J. Fay,et al.  Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Groothuis,et al.  Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. , 1986 .

[12]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[13]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[14]  T. Kokunai,et al.  Synergistic effect of perfluorochemicals on BCNU chemotherapy. Experimental study in a 9L rat brain-tumor model. , 1982, Journal of neurosurgery.

[15]  R. Geyer.  Oxygen transport in vivo by means of perfluorochemical preparations. , 1982, The New England journal of medicine.

[16]  V. Levin.  Chapter 13 – CLINICAL PHARMACOLOGY OF THE NITROSOUREAS1 , 1981 .

[17]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[18]  B. Teicher,et al.  The hypoxic tumor cell: a target for selective cancer chemotherapy. , 1980, Biochemical pharmacology.

[19]  S. Crooke,et al.  Cisplatin : current status and new developments , 1980 .

[20]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[21]  T. A. Connors.  Alkylating agents. , 1990, Cancer chemotherapy and biological response modifiers.

[22]  J. Edmonson,et al.  Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. , 1965, Cancer research.